A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Inclusion Criteria:

J4M-MC-PWMP

• Have a history of at least 1 unsuccessful effort to lose sufficient body weightafter participation in a structured lifestyle modification program (diet andexercise counseling for at least 3 months) prior to screening.

• Obesity as defined by BMI equal to or above the 95th percentile for age and sex (onage- and gender-specific growth chart [CDC-NCHS, 2022]); OR

• Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,

• hypertension

• type 2 diabetes (T2D)

• prediabetes

• dyslipidemia

• obstructive sleep apnea

• metabolic dysfunction-associated steatohepatitis (MASH) or metabolicdysfunction-associated steatotic liver disease (MASLD)

Exclusion Criteria:

J4M-MC-PW01

• Prepubertal (Tanner stage 1)

• Have a self-reported, or by parent or legal guardian where applicable, decrease inbody weight greater than 5 kilograms (kg) (11 pounds) within 90 days beforescreening

J4M-MC-PWMP

• Have undergone or plan to undergo weight reduction procedure during the study, suchas, but not limited to:

• gastric bypass

• sleeve gastrectomy

• restrictive bariatric surgery, such as Lap-Band® gastric banding, or

• any other procedure intended to result in weight reduction.

• Have a diagnosis that is a secondary cause of obesity or have a history of abruptonset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic,syndromic, or endocrine causes.

• Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state.

• Have HbA1c >9.0% (75 mmol/mol) as measured by central laboratory at screening.

• Have a family or personal history of medullary thyroid carcinoma or MultipleEndocrine Neoplasia Syndrome Type 2.